Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Entasis Therapeutics Holdings Inc. stock logo
ETTX
Entasis Therapeutics
$2.19
$2.19
$1.40
$3.88
$104.80M1.33239,104 shs800 shs
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
$0.33
-7.1%
$0.36
$0.22
$4.79
$13.67M-0.281.10 million shs303,971 shs
Q Biomed Inc. stock logo
QBIO
Q Biomed
$0.00
$0.00
$0.03
N/A2.1914,326 shsN/A
Trevena, Inc. stock logo
TRVN
Trevena
$0.94
-5.5%
$1.09
$0.73
$7.85
$897K0.612,066 shs462 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Entasis Therapeutics Holdings Inc. stock logo
ETTX
Entasis Therapeutics
0.00%0.00%0.00%0.00%0.00%
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
-7.12%+14.55%-24.32%+1.82%-83.17%
Q Biomed Inc. stock logo
QBIO
Q Biomed
0.00%0.00%0.00%0.00%-75.00%
Trevena, Inc. stock logo
TRVN
Trevena
-5.50%-0.51%-7.41%-17.24%-83.34%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Entasis Therapeutics Holdings Inc. stock logo
ETTX
Entasis Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
1.9335 of 5 stars
3.02.00.00.02.70.01.3
Q Biomed Inc. stock logo
QBIO
Q Biomed
N/AN/AN/AN/AN/AN/AN/AN/A
Trevena, Inc. stock logo
TRVN
Trevena
1.8741 of 5 stars
3.03.00.00.02.80.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Entasis Therapeutics Holdings Inc. stock logo
ETTX
Entasis Therapeutics
0.00
N/AN/AN/A
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
2.00
Hold$3.38923.04% Upside
Q Biomed Inc. stock logo
QBIO
Q Biomed
0.00
N/AN/AN/A
Trevena, Inc. stock logo
TRVN
Trevena
2.00
Hold$5.00434.64% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Entasis Therapeutics Holdings Inc. stock logo
ETTX
Entasis Therapeutics
$7M14.97N/AN/A$0.66 per share3.32
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
N/AN/AN/AN/A$0.91 per shareN/A
Q Biomed Inc. stock logo
QBIO
Q Biomed
$280KN/AN/AN/AN/AN/A
Trevena, Inc. stock logo
TRVN
Trevena
$443K2.02N/AN/A($11.07) per share-0.08
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Entasis Therapeutics Holdings Inc. stock logo
ETTX
Entasis Therapeutics
-$47.14M-$1.12N/AN/AN/AN/A-145.48%-103.75%N/A
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
-$67.56M-$1.70N/AN/AN/AN/A-162.15%-120.05%8/11/2025 (Estimated)
Q Biomed Inc. stock logo
QBIO
Q Biomed
-$2.05MN/A0.00N/AN/AN/AN/AN/AN/A
Trevena, Inc. stock logo
TRVN
Trevena
-$40.29M-$47.04N/AN/AN/AN/AN/A-119.55%8/6/2025 (Estimated)

Latest QBIO, ETTX, LPTX, and TRVN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
-$0.38-$0.37+$0.01-$0.37N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Entasis Therapeutics Holdings Inc. stock logo
ETTX
Entasis Therapeutics
N/AN/AN/AN/AN/A
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
N/AN/AN/AN/AN/A
Q Biomed Inc. stock logo
QBIO
Q Biomed
N/AN/AN/AN/AN/A
Trevena, Inc. stock logo
TRVN
Trevena
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Entasis Therapeutics Holdings Inc. stock logo
ETTX
Entasis Therapeutics
N/A
1.65
1.65
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
N/A
2.41
2.41
Q Biomed Inc. stock logo
QBIO
Q Biomed
N/AN/AN/A
Trevena, Inc. stock logo
TRVN
Trevena
N/A
2.42
2.42

Institutional Ownership

CompanyInstitutional Ownership
Entasis Therapeutics Holdings Inc. stock logo
ETTX
Entasis Therapeutics
6.91%
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
30.46%
Q Biomed Inc. stock logo
QBIO
Q Biomed
N/A
Trevena, Inc. stock logo
TRVN
Trevena
13.56%

Insider Ownership

CompanyInsider Ownership
Entasis Therapeutics Holdings Inc. stock logo
ETTX
Entasis Therapeutics
6.50%
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
7.50%
Q Biomed Inc. stock logo
QBIO
Q Biomed
28.20%
Trevena, Inc. stock logo
TRVN
Trevena
2.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Entasis Therapeutics Holdings Inc. stock logo
ETTX
Entasis Therapeutics
5147.85 million44.74 millionNot Optionable
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
4041.44 million38.33 millionOptionable
Q Biomed Inc. stock logo
QBIO
Q Biomed
3N/AN/ANot Optionable
Trevena, Inc. stock logo
TRVN
Trevena
40959,000841,000Optionable

Recent News About These Companies

Trevena, Inc. (TRVN) - Yahoo Finance
JMP Securities downgrades Trevena (TRVN) to a Hold
Lyme Regis town councillor John Trevena stand down
Trevena appoints new financial chief
Trevena Appoints Katrine Sutton as New CFO
HC Wainwright & Co. Downgrades Trevena (TRVN)
Why Trevena (TRVN) Stock Is Down 43% Today
Trevena, Inc. Faces Delisting from Nasdaq
Trevena Announces Receipt of Nasdaq Delisting Notification
Learn to Evaluate (TRVN) using the Charts

New MarketBeat Followers Over Time

Media Sentiment Over Time

Entasis Therapeutics stock logo

Entasis Therapeutics NASDAQ:ETTX

Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts. Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc.

Leap Therapeutics stock logo

Leap Therapeutics NASDAQ:LPTX

$0.33 -0.03 (-7.12%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$0.34 +0.01 (+3.67%)
As of 07/11/2025 05:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Q Biomed stock logo

Q Biomed OTCMKTS:QBIO

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.

Trevena stock logo

Trevena NASDAQ:TRVN

$0.94 -0.05 (-5.50%)
As of 07/11/2025 12:43 PM Eastern

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.